Explore 3 Stock Ideas & Industry Insights Download Free Report

Grey Wolf Animal Health Corp.

Company price
1.65 CAD 0.00(0%)
Last update at 2026-11-03T14:30:00Z
Market Cap
50.60M
P/E
29.60

Momentum Score

…

Grey Wolf Animal Health Corp. operates as an animal health and wellness company in Canada. The company operates in two segments, Animal Health Business Unit and Pharmacy Business Unit. It engages in the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics, as well as offers pharmaceuticals for the human and animal health markets. The company provides dexmedetomidine hydrochloride oromucosal gel under the SILEO name; sedative analgesic and reversing agents for companion animals under the SEDAJECT and ATAJECT names; prescription drugs under the THYRO-TABS CANINE name; and wound care products, including medical tubes, viscose net dressings, alginate dressing, absorbent foam dressing, superabsorbent dressing, cohesive bandages, and silicone perforated tapes, as well as medical pet shirt protective wear products, such as pet shirt, pets boot, head cover, and leg sleeves. It also offers disposables comprising syringes, needles, and IV catheters; and nutraceuticals, as well as equine health products. The company is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.65
Low
1.65
High
52 Week Price Range
0.90
Low
1.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Grey Wolf Animal Health Corp. is a Canada-based veterinary health company listed on the TSX Venture Exchange that, according to public filings, develops and commercializes animal health products and related services. Long-term growth drivers may include rising demand for animal protein and companion-animal care, expansion of its product pipeline and distribution reach, and consolidation in the animal-health sector that could support scale. The company appears positioned to benefit from sector growth but remains a small-cap developer with limited public visibility.

Material risks include limited public disclosure, early-stage execution and financing risk, regulatory approval and compliance requirements for veterinary products, and competition from larger established firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.65
Dividend Yield
-
Revenue TTM
33.47M
Revenue Per Share
0.99
Gross Profit TTM
17.76M
Debt / Equity
-
ROE
2.92%
Net Debt
17.39M
ROCE
6.96%
Diluted EPS TTM
0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 2.38M 1.39M 1.10M 1.75M -1.89M
Net income 1.66M 0.70M 0.61M 2.54M -0.97M
Selling general administrative 12.94M 10.64M 10.06M 10.62M 6.01M
Gross profit 19.06M 13.76M 12.83M 11.56M 7.15M
Reconciled depreciation 2.70M 1.53M 1.45M 1.56M 1.12M
Ebit - - - - 0.13M
Operating income 4.06M 1.91M 1.55M -0.36M 0.07M
Interest expense 1.77M 0.66M 0.60M 6.68M 1.66M
Tax provision 0.72M 0.69M 0.49M -0.80M -0.92M
Interest income 0.11M 0.20M 0.15M - -
Net interest income -1.66M -0.46M -0.45M -6.68M -1.66M
Income tax expense - - - - -0.92M
Total revenue 35.76M 26.83M 25.41M 22.64M 13.10M
Total operating expenses 31.71M 24.92M 23.86M 22.99M 13.03M
Cost of revenue 16.70M 13.07M 12.58M 11.07M 5.95M
Total other income expense net -0.02M -0.05M -0.01M 8.78M -0.31M
Net income from continuing ops 1.66M 0.70M 0.61M 2.54M -0.97M
Net income applicable to common shares - - - - -0.97M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 64.53M 65.60M 41.41M 39.31M 36.23M
Intangible assets 16.66M 18.34M 9.52M 10.50M 11.58M
Total liab 33.96M 36.77M 16.32M 15.06M 32.16M
Total stockholder equity 30.56M 28.83M 25.09M 24.25M 4.08M
Other current liab - - - - 4.06M
Common stock - - - - 9.69M
Capital stock 31.53M 31.53M 28.58M 28.58M 9.69M
Retained earnings -6.32M -7.98M -8.69M -9.29M -11.84M
Other liab - - - - 1.83M
Good will 24.20M 24.20M 13.89M 13.89M 13.89M
Cash 7.67M 6.41M 7.78M 6.86M 4.35M
Total current liabilities 6.21M 6.17M 5.42M 4.99M 19.51M
Net debt 17.39M 20.46M 1.40M 3.25M 18.77M
Short long term debt 2.17M 2.07M 1.06M 1.06M 13.10M
Other stockholder equity - - - - 5.33M
Property plant equipment - - - - 2.29M
Total current assets 16.07M 14.51M 14.36M 12.89M 8.47M
Net tangible assets - - - - -21.40M
Net receivables 2.25M 2.21M 1.69M 1.95M 1.12M
Long term debt 22.88M 24.80M 8.12M 9.05M 10.03M
Inventory 5.56M 5.48M 4.63M 3.76M 2.87M
Accounts payable 3.68M 3.99M 4.12M 3.69M 2.22M
Non current assets total 48.46M 51.09M 27.06M 26.42M 27.76M
Capital lease obligations 0.42M 0.73M 0.74M 0.92M 0.92M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -20.47M -0.28M 4.36M -23.24M
Change to liabilities - - - - 0.79M
Total cashflows from investing activities - - - - -23.24M
Net borrowings -2.06M 17.37M -1.22M - 22.29M
Total cash from financing activities -2.06M 17.35M -1.22M -1.14M 23.32M
Change to operating activities - - - - -0.07M
Net income 1.66M 0.70M 0.61M 2.54M -0.97M
Change in cash 1.25M -1.37M 0.93M 2.51M 2.22M
Begin period cash flow 6.41M 7.78M 6.86M 4.35M 2.13M
End period cash flow 7.67M 6.41M 7.78M 6.86M 4.35M
Total cash from operating activities 3.83M 1.75M 2.43M -0.71M 2.14M
Issuance of capital stock - - - 0.00M 2.48M
Depreciation 2.70M 1.53M 1.45M 1.56M 1.12M
Change to inventory -0.08M -0.39M -0.86M -0.90M -0.21M
Change to account receivables - - - - 0.55M
Other cashflows from financing activities - - - - -1.45M
Change to netincome - - - - 0.80M
Capital expenditures 0.52M 0.53M 0.28M 0.05M 0.01M
Change in working capital -0.90M -0.94M -0.14M -0.61M 1.06M
Stock based compensation 0.08M 0.09M 0.23M 0.21M 0.18M
Other non cash items 0.09M 0.24M 0.13M 5.52M 1.48M
Free cash flow 3.31M 1.21M 2.15M -0.76M 2.12M

Peer Comparison*

Sector: Consumer Cyclical Industry: Personal Services

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WOLF
Grey Wolf Animal Health Corp.
-
-%
1.65 29.60 - 1.51 1.66 1.91 9.98
MNLX
MiniLuxe Holding Corp
0.05
12.82%
0.44 - - 2.12 5.79 1.81 -2.75
RMB
Rumbu Holdings Ltd.
-
-%
0.50 - - 1.33 17.12 2.34 27.66
WPR
CANPR Technology Ltd.
-
-%
0.04 - - 0.48 0.73 0.50 1.41

Profile*

Grey Wolf Animal Health Corp.

Grey Wolf Animal Health Corp. operates as an animal health and wellness company in Canada. The company operates in two segments, Animal Health Business Unit and Pharmacy Business Unit. It engages in the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics, as well as offers pharmaceuticals for the human and animal health markets. The company provides dexmedetomidine hydrochloride oromucosal gel under the SILEO name; sedative analgesic and reversing agents for companion animals under the SEDAJECT and ATAJECT names; prescription drugs under the THYRO-TABS CANINE name; and wound care products, including medical tubes, viscose net dressings, alginate dressing, absorbent foam dressing, superabsorbent dressing, cohesive bandages, and silicone perforated tapes, as well as medical pet shirt protective wear products, such as pet shirt, pets boot, head cover, and leg sleeves. It also offers disposables comprising syringes, needles, and IV catheters; and nutraceuticals, as well as equine health products. The company is headquartered in Toronto, Canada.

Bay Adelaide ? West Tower, Toronto, ON, Canada, M5H 2R2

Name Title Year Born
Ms. Angela Cechetto Chief Exec. Officer NA
Dr. Ian Sandler Founder, Director & CVMO NA
Mr. Kevin S. Palmer C.A., CPA, M.B.A. Chief Financial Officer NA
Mr. Brandon Mair-Wren VP of Operations NA
Mr. Murray Roach C.C.O. NA
Ms. Angela Cechetto CEO & Secretary NA
Dr. Ian Sandler Founder, Chief Veterinary Medical Officer & Director NA
Mr. Brandon Mair-Wren Vice President of Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…